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Response to antidepressant (AD) treatment may be a more
polygenic trait than previously hypothesized, with many genetic
variants interacting in yet unclear ways. In this study we used
methods that can automatically learn to detect patterns of
statistical regularity from a sparsely distributed signal across
hippocampal transcriptome measurements in a large-scale ani-
mal pharmacogenomic study to uncover genomic variations
associated with AD. The study used four inbred mouse strains
of both sexes, two drug treatments, and a control group (esci-
talopram, nortriptyline, and saline). Multi-class and binary
classification using Machine Learning (ML) and regularization
algorithms using iterative and univariate feature selectionmeth-
ods, including InfoGain, mRMR, ANOVA, and Chi Square, were
used to uncover genomic markers associated with AD response.
Relevant genes were selected based on Jaccard distance and
carried forward for gene-network analysis. Linear association
methods uncovered only one gene associated with drug treat-
ment response. The implementation of ML algorithms, together
with feature reduction methods, revealed a set of 204 genes
associated with SSRI and 241 genes associated with NRI
response. Although only 10% of genes overlapped across the
two drugs, network analysis shows that both drugs modulated
the CREB pathway, through different molecular mechanisms.
Through careful implementation and optimisations, the algo-
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rithms detected a weak signal used to predict whether an animal
was treated with nortriptyline (77%) or escitalopram (67%) on
an independent testing set. The results from this study indicate
that the molecular signature of AD treatment may include
a much broader range of genomic markers than previously
hypothesized, suggesting that response to medication may be
as complex as the pathology. The search for biomarkers of
antidepressant treatment response could therefore consider a
higher number of genetic markers and their interactions.
Through predominately different molecular targets and mecha-
nisms of action, the two drugsmodulate the sameCreb1 pathway
which plays a key role in neurotrophic responses and in inflam-
matory processes.
 2016 The Authors. American Journal of Medical Genetics Part B: Neuropsy-
chiatric Genetics Published by Wiley Periodicals, Inc.
Key words: machine learning; SVM; transcriptomics; anti-
depressants; SSRI
INTRODUCTION
Major depressive disorder (MDD) is a pervasive psychiatric disor-
der characterized by a number of clinical symptoms including:
persistent low mood, anhedonia, insomnia, low energy, feelings of
guilt, and ideation of death or suicide. MDD is also associated with
a range of social impairments, including educational and occupa-
tional problems and with an increased risk of developing systemic
disease, such as cardiovascular disease and Type 2 diabetes [Mezuk
et al., 2008; Goldstein et al., 2015]. Epidemiological studies
have shown links between MDD and increased levels of mortality,
due to either suicide or resulting diseases [Ferrari et al., 2013;
Mullins et al., 2014]. In the US, MDD was reported to have a
lifetime prevalence of 16.2% and comorbidity with at least one
other DSM-IV (diagnostic statistical manual IV) disorder of
72.1%, representing a major public health concern [Kessler
et al., 2003].
Although quantitative genetic studies report moderate herita-
bility estimates (between 40% and 50%), progress in uncovering
the molecular substrate underpinning MDD has been slow
[Levinson, 2006]. Highly powered GWAS (Genome-Wide Associ-
ation Study) have been less successful in uncovering common
genetic variation associated with MDD than with other Axis-I
psychiatric disorders such as Schizophrenia [Schizophrenia Psy-
chiatric Genome-Wide Association Study (GWAS) Consortium,
2011]. To date, the largest publishedmega-GWASonMDDyielded
negative findings [Major Depressive DisorderWorking Group of
the Psychiatric Consortium et al., 2013]. Although GWAS hits for
MDD have been recently announced, they still explain only a
fraction of the variation in the disorder [Hyde et al., 2016]. One
possible explanation for the difficulty in uncovering molecular
variants associated with the pathology is that MDD is a highly
heterogeneous disorder and selection of cases for GWAS studies
still relies on clinical algorithms centered on symptom persistence
and count that may be independent of any aetiological consider-
ations [Malki et al., 2014]. This could point at multiple subtypes of
depressive disorder and to genetic overlap between cases and
controls. A second explanation is that depression is a complex,
highly polygenic trait with a number of genes and environmental
factors interacting in yet unclear ways [Uher, 2014]. It is likely that
in isolation, no common variant of small penetrance can signifi-
cantly account for the disorder. Traditional methods of analysis for
Genome-Wide data typically rely on a linear or logistic regression
with an additive model that explores the association between single
markers and a binary outcome. However, this loci-by-loci associa-
tion method is poorly suited to capture gene–gene interaction
effects (epistasis) or to consider the effects of clusters of genes
across wide genomic distances.
The need to find fast and effective treatment for the pathology
even in the absence of known aetiology remains a priority. To date
there are over 30 pharmacological agents that have been shown to
be effective for the treatment of MDD in clinical trials but less than
50% of patients respond favorably to the first prescribed drug
[Thase et al., 2001]. It has long been hypothesized that response to
drug treatment may be a less polygenic trait than the pathology
itself. However, candidate gene studies informed by the known
pharmacodynamic and pharmacokinetic mode of action of several
classes of antidepressant drugs have yet to uncover a reliable genetic
biomarker with clinical significance [Uher et al., 2012]. To date,
the largest Genome-Wide Pharmacogenetic Association Study on
antidepressant treatment response has yielded negative results,
suggesting that response to pharmacotherapy may itself be a
complex, highly polygenic trait [Tansey et al., 2012].
Complex traits, including Axis-I psychiatric disorders, have a
multidimensional genetic architecture consisting of many small
effect-size variants, which only together through regulatory,
stochastic events, gene–gene (epistasis) and gene-environment
interactions can account for individual differences in a clinically
meaningful way. As a result, identification of groups of genes
showing a moderate change in expression, but together signifi-
cantly associated with the trait of interest, is likely to provide a
powerful insight into the underlying molecular mechanisms by
highlighting a mutual function [Mootha et al., 2003; Subramanian
et al., 2005]. Multivariate methods of analysis offer advantages as
identification of individual genes associated with complex traits
is often difficult to interpret from a biological stand-point and
results are often poorly reproduced [Frantz, 2005].
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Supervised machine learning approaches are a powerful tool for
the classification of multidimensional data. Several methods in
statistical learning use a multivariate approach to the entire dataset
and are capable of considering interactions [Iniesta et al., 2016].
Several optimization techniques, including kernel functions and
model parameters, allow the algorithms to detect patterns of
statistical regularity across a sparsely distributed signal and use
this information to make meaningful classifications and predic-
tions. Application of statistical learning approaches to Psychiatry is
more common in the classification of blood cell transcriptomic
data [Marquand et al., 2008; Schwarz et al., 2010]. Although these
studies point at the possibility of improving diagnosis of psychiat-
ric disorders by successfully identifying trait-specific gene expres-
sion signatures, they have not been widely used to uncover
etiological mechanisms. Reports of these methods successfully
dissecting complex psychiatric disorders strongly implies that
the application of these methods to transcriptomic data, derived
from disorder-relevant brain tissue, could provide insight into
underlying molecular and neurobiological mechanisms.
In this studywe have evaluated, optimized and applied a range of
machine learning algorithms to a mouse pharmacogenomic study
from the GENDEP project [Malki et al., 2011]. By using this
approach, we aim to identify groups of genes, and therefore
biological pathways, underlying the differential response to two
of the most popular classes of antidepressant drugs: Selective
serotonin reuptake inhibitors (SSRIs) and norepinephrine reup-
take inhibitor (NRIs).
MATERIALS AND METHODS
Design
The Genome-based Therapeutic Drugs for Depression (GENDEP)
is a large-scale, multidisciplinary, multicenter study that focuses on
the prediction of therapeutic responses and adverse effects to AD
and on the molecular aetiology of Major Depressive Disorder
(MDD) [Uher et al., 2010]. In this study we used hippocampal
gene expression from an animal model of depression in a discov-
ery-replication design. The hippocampus was chosen at the time of
the study because it is a brain region that can be dissected
consistently in mouse and has been implicated in the regulation
of mood in human studies [Santarelli et al., 2003; Surget et al.,
2011]. Hippocampal neurogenesis has been repeatedly demon-
strated as an important process for the behavioural effects of
antidepressants in both rodents and non-human primates [Perera
et al., 2011]. The study used four strains of well-characterized
inbred mice (129S1/SvImJ, C57LB/6J, DBA/2J, and FVB/NJ), two
depressogenic protocols and a control condition (maternal sepa-
ration, chronic mild stress and control), two sexes, two drug
administration regimes (chronic and acute) and two drug treat-
ments (nortriptyline, escitalopram, or saline). This yielded a
balanced design with 144 experimental cells. Supervised and
non-supervised machine-learning and regularization methods,
training and testing on independent samples were applied using
probesets as features and drug (active drug or control) as outcome
classes. The high-dimensional structure data were first explored in
a multi-class design (three classes; two drugs, and one control
condition) and then using a simpler binary classification, which
compared each of the two drugs individually against a control
(saline) condition. Probe-sets were treated as feature variables and
each of the animals as instances that can be represented as data
points in a 37,231 (number of probes) dimensional feature space.
Together with the corresponding factor (response) labels, super-
vised learning and penalized regularization approaches have been
used to classify drug labels into their respective classes. Feature
reductionmethods were then used to extract those feature sets with
higher probability of association with outcome class.
Animals
A total of 144male and female mice from the following four strains
were used in this study in a balanced design: 129S1/SvImJ (129),
C57LB/6J (C57), DBA/2J (DBA), and FVB/NJ (FVB). Each mouse
represents an experimental group, which differs by combinations
of strain, sex, stress, AD, and AD administration schedule. Animals
used for this expression study were not behaviorally tested. How-
ever, a parallel large-scale behavioral study with a matching design
was previously conducted on a different set of animals [Binder
et al., 2011]. All animals were bred in the barrier unit at the Institute
of Psychiatry, London, UK. All housing and experimental proce-
dures were carried out in accordance with the UK Home Office
Animals (Scientific Procedures) Act 1986.
Antidepressant Drugs
The GENDEP project used the same two-antidepressant drugs
across all of its treatment arms: the NRI nortriptyline (4mg/kg)
and escitalopram (5mg/kg) representing the most two common
classes of AD’s. Clinical trials have shown that both classes of drugs
are effective for the treatment of MDD although they have distinct
modes of action [Sanchez and Hyttel, 1999; Sanchez et al., 2003].
SSRIs have no effect on noradrenaline reuptake while NRIs have up
to 100 times higher affinity for the noradrenaline compared to the
serotonin neurotransmitter.
Dosage Pilot Study
Apilot studywas conducted to determine a drug dosage that would
elicit a behavioral response in the absence of an effect of locomotion
or anxiety. Based on the pilot study, a dose of 5mg/kg of escita-
lopram and 4mg/kg of nortriptyline was chosen. Two drug ad-
ministration regimes were explored (chronic-14 days and acute
24 hr). All animals not in the chronic condition were injected with
saline for 14 days to balance any stress from the intraperitoneal
injections. Linear models did not reveal an effect of drug adminis-
tration regime. Further information on the pilot study is available
elsewhere [Binder et al., 2011].
mRNA Extraction and Gene Expression Profiling
Brainswere dissected and hippocampi frozen ondry ice. Total RNA
was extracted from frozen hippocampal tissue and 3-ug RNA was
processed using the One Cycle Target Labelling kit (Affymetrix,
Santa Clara, CA) and hybridized to the mouse MOE430v2
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Gene ExpressionArray (Affymetrix) following standardAffymetrix
protocols. At the time of the experiment, the Affymetrix Mouse
MOE430v2 provided the most comprehensive coverage of the
mouse genome. These arrays contain multiple probe pairs for
each of the 45,101 probe sets, providing several independent
measures for 39,000 transcripts corresponding to over 19,000
well characterized mouse genes.
Statistical Analysis
Data from 144 Affymetrix mouse whole-genome oligonucleotide
arrays (MOE430v2) was normalized and summarized into probe
sets by Robust Multichip Average (RMA) method [Irizarry et al.,
2003]. Quality control of the resulting scans, including raw inten-
sity distributions, profile correlations, and multivariate analysis
indicated inconsistent quality with ten arrays, which were removed
andQC analysis repeated. As part of the QC procedure, r and post-
normalisation boxplots of probe log-intensity distributions were
plotted to compare median intensities across arrays. These showed
near identical distribution patterns following RMA normalization.
Density plots of log-intensity distribution of each array were
subsequently superimposed to check for any deviation between-
arrays. Identification of intensity-dependent biases was performed
by visual inspection of MA plots, which are derived by computing
pairwise-comparison of log-intensity of each array to a reference
array. The Relative Log Expression (RLE) values were then com-
puted by calculating the ratio between the expression of a probe-set
and the median expression of this probe-set for each probe sets
across all arrays. The results show a ratio of around 0 on a log-scale,
which is expected as most probe-sets should remain invariant
across the array. Percentage of present calls plots using Affymetrix
MAS 5.0 show good consistency across arrays. Positive and nega-
tive controls distributions were plotted to check for non-uniform
hybridization or gridding problems, both showing clustering
around a (0,0) center. RNA quality control was conducted using
30/50 ratio for beta-actin and GAPDH. Values were well within
commonly used threshold of three for beta-actin and 1.25 for
GAPDH showing consistently good quality. RNA degradation
plots were also visually inspected to explore the directionality of
degradation from the 50 to the 30 end and for consistency in the rate
(slope) of degradation. Lastly, we used, heatmaps, PCA and
hierarchical clustering to uncover potential outliers but these
were not detected in our samples (Supplementary Materials 1).
Probe sets that were systematically absent (based on the MAS 5.0
detection call) across all the arrays were also removed leaving
37,231 out of the original 45,101 probe sets. General linear models
were run on the 134 arrays using drug, stress and strain as fixed
effects and sex and dose (acute and chronic) included as covariate
in the model. Analysis of Covariance (ANCOVA) did not reveal a
significant effect of these two covariates. Any variance explained by
these two factors was removed using linear regression and residuals
were carried forward for analysis. For comparison purposes, we
conducted a traditional linear association analysis using expression
as predictor and drug class as outcome. Only one probe-set
associated with drug treatment survived FDR correction for mul-
tiple testing. This result was used to provide a comparison baseline
to the methods used in this study.
MACHINE LEARNING APPROACH
Classification
In statistical learning, a classification task is one wherein we have a
dataset S ¼ xi; yið Þ
 N
i¼1, where N is the number of samples,
xi2XM contains the characteristics of the sample i, and yi2Y is
the class to which the sample belongs. In this study, we explored
both amulti-class and a simpler dichotomousmethod using binary
classifiers and the one-versus-all strategy, which consists in training
n different classifiers, where n is the number of classes. For each
class, a classifier is trained with the samples belonging to that class
as positive and the rest as negative.Once the n classifiers are trained,
a sample is assigned to the class which gets the largest confidence.
For analysis we used the Python package Scikit-learn, which fits the
provided data relying on Regularized Logistic Regression, using
Stochastic Gradient Descent (SGD) [Pedregosa et al., 2011].
Logistic Regression
Logistic Regression is a probabilistic classifier model that fits a
vector of coefficients so that the computation of a logistic function
gives the probability of a sample belonging to a certain class. For
logistic regression the model can be defined as:
L y; f xð Þð Þ ¼ y⁢logp1 x;wð Þ þ 1 yð Þlog 1 p1 x;wð Þð Þ:
Support Vector Machines (SVMs)
SVMs with soft margins and Radial Basis Functions (RBF) are
commonly used for classification purposes. SVMs classify data by
finding an optimal separating hyper-plane between data points of
different classes [Boser et al., 1992]. SVMs are effectively binary
classifiers which in this study have been extended to address a
multi-class problem using the one-versus-all method. This method
was chosen for interpretability of results as each class is represented
by one classifier only; knowledge on membership to a class can
simply be obtained by inspecting the classifier.
l2, l1, and Elastic Net Regularization
A traditional logistic regressionmodelworks as a loss function to be
minimized when fitting the model. However, it is possible to
introduce additional penalty terms to obtain penalized complex
models. The ℓ1—Norm Regularization (ridge) model used, com-
putes the squared magnitude of the coefficients vector in the
Euclidean space.
V wð Þ ¼ kwk22 ¼ S
M
i¼1
w2i
and reduces the magnitude of the coefficients [Hoerl and Kennard,
1970]. When closely correlated features exist, they are assigned
similar coefficients, so that the correlated values are averaged. The
ℓ1—Norm Regularization (lasso)
V wð Þ ¼ kwk1 S
M
i¼1
wij j
enforce coefficients of irrelevant features to be exactly 0. Therefore,
it implicitly discards irrelevant or redundant features. ℓ1Norm
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Regularization has an important limitation: in the case MN, at
most N features are selected. From a group of highly correlated
features,as in probe sets, it tends to select only one, dropping
features instead of averaging them. The Elastic Net Regularization
[Zou and Hastie, 2005] combines both ℓ1 and ℓ2 norms giving the
penalization term
V wð Þ ¼ akwk1 þ 1
2
1 að Þkwk22;
where a regulates the balance between the two norms. The two
penalties have different effects. On the one hand, ℓ1 norm encour-
ages irrelevant feature weights to be zero acting as feature selection.
On the other hand, ℓ2 norm penalty produces weight vectors with
smaller values. Balance between both penalties is achieved through
methods including cross validation.
This type of regularization seems to be a good choice for the kind
of data used in this project from a theoretical perspective. The
reasoning driving this approach is that genes belonging to biologi-
cal pathways interact with signals andwith each other (epistasis), to
carry out their tasks; this scenario is a goodmatch to the advantages
of the Elastic Net regularization method [Zou and Hastie, 2005].
Feature Selection and Filters
Feature Selection is the process whereby only a subset of the
original features are kept, reducing the complexity of the data
space to explore. Four different filters were used: InfoGain,mRMR,
ANOVA, and Chi Squared. For each of these filters the following
procedure was undertaken: 10% of the data are held out for testing;
the remaining 90% is discretized (except for ANOVA) and used to
run the filter and obtain a ranking of the features. Subsequently,
different classifiers were trained with varying number of the best
scoring features and then tested on the held out data. For training
data sets, we performed a 10-fold cross validation grid search to
find the best set of parameters and then fitting the model. The
computation of Information Theory measures requires discrete
data which we performed in two ways: Naive discretization
achieved by splitting the data in 10 equal bins from the minimum
value to the maximum and by expression-based discretization,
which is based on the concepts of over and under expression of
genes. Values were assigned to1, 1, or 0 depending on whether it
was under/over expressed or not significantly differentially
expressed, respectively. A gene was considered over expressed if
it was more than two standard deviations away from the mean
expression across samples in a positive direction. Analogously
expressions falling in the negative side were deemed under
expressed. The expressions lying close to themean were considered
not differentially expressed.
Recursive Feature Elimination (RFE)
RFE (Algorithm 1) is an iterative method that begins by fitting a
model with all of the features. It then removes the features with
small contributions and refits the model with the remaining
features and recursively continues this process until a minimum
of features remains [Guyon et al., 2002]. This strategy was used to
select a desired number of features and choose the subset size which
minimizes the error.We applied RFE in combination with both the
SVM and regularised logistic regression.
Algorithm 1: Implementation of the RFE algorithm. The Ef (w)
is representing the loss function to optimize for the classifier
Input: k Number of features to select
Input: m Step
Input: f Classifier
Input:
S¼ {All features}
while S k do
W argminwef (w)
S S\{Features with smallest coefficient sin W}
SS S
end while
return Sk Skþm Skþ2m... SM
Evaluation Metrics and Features Comparison
Classification accuracy, expressed as percentage of samples cor-
rectly classified, on testing dataset or following Stratified Cross
Validation were used as assessment metrics [Braga-Neto and
Dougherty, 2004]. Jaccard distance, which indexes the degree of
similarity between two sets of features, was used to compare the
selected subsets of features to ascertain the degree to which they
were consistent across the different methods used.
dJ A;Bð Þ ¼ A [ Bj j A \ Bj j
A [ Bj j :
The Jaccard distance can take values in the interval [0,1], being 1
for disjoint sets and 0 for equivalent sets.
Gene Networks and Pathway Analysis
MetaCoreTM (https://portal.genego.com/) was used to explore the
molecular association between genes lists obtained from the two
binary comparison (escitalopram vs. control and nortriptyline vs.
control) and known pathways maps and functional networks.
MetaCoreTM scores and prioritizes networks and pathways based
on the relevance of the gene sets uploaded. The software evaluates
the magnitude of the intersection between the uploaded genes and
the set of genes corresponding to a network module using different
statistical metrics including P values and G-scores. P values are
calculated based on hypergeometric distributions and used to
establish whether saturation with the genes of interest is higher
than random.When exploring signaling cascades, this allows one to
evaluate if a network contains any fragments of well understood
(canonical) signaling pathways. The G-score is anothermetric used
by MetaCoreTM that effectively modifies the Z-score based on the
number of the linear canonical pathway fragments contained
within the network. A network highly saturated with reference
genes and containing several canonical pathways will achieve a
higher G-score. In this study we have explored the top ranking
networks by P-value and by G-score and reported the highest
associated functional pathway. These pathways were also com-
pared to understand potential dissimilarities between the two drug
comparisons.
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RESULTS
Multi-Class Comparisons and Methods Selection
The first analysis empirically evaluated the performance of several
statistical learningmethods with different levels of feature selection
in a 3-way, multi-class design with two drug groups and a control
group. Given the three possible decision class at outcome (nor-
triptyline, escitalopram, and saline), chance levels were considered
at 33.3%. The results show that support vector machines with
InfoGain using naive discretization was able to classify animals by
treatment group above chance levels and outperformed both ℓ1
andℓ2 fnorm regularizationmethods and Elastic Net, which clearly
yielded poor results (Table I). Indeed, the classification of animals
by drug treatment condition seemed sensitive to the statistical
methodology used.
Across all methods used, the results get progressively weaker as
we reduce the number of predictive features. This suggests that the
molecular perturbations caused by antidepressant drugs are
sparsely distributed across a very broad genomic region, pointing
at the highly polygenic nature of AD response. It is likely that AD
drugs affect in excess of 5,000 genes by a very small amount, which
may explain the generally weak results reported using traditional
linear association methods. The strongest classification consider-
ing error terms was achieved with the inclusion of 10,000 probe-
sets. Below 1,000 features none of the methods was able to classify
animals into treatment group above chance levels in a 3-waymulti-
class design.
Binary Classifications—Drug Versus Control
Differences between treated and control animals were also explored
as part of a simpler, two-class solution for each of the two drugs
separately. The first binary analysis usedmRNA expression levels to
classify animals into nortriptyline or control groups while the
second analysis classified animals into escitalopram or control
groups. A summary of results for the nortriptyline versus control
group is presented in Table II.
The highest classification accuracy was achieved with an SVM
using radial basis function and 30,000 probe sets (77%). The results
are consistent with themulti-class analysis both in terms of number
of features likely to be involved and in terms of the statistical
methods used. The second binary comparison was conducted on
the escitalopramor control groups. The results of this analysis show
that it was possible to classify animals above chance level (>67%).
However, classification was only possible using feature reduction
(the best results obtained using ANOVA) suggesting a less poly-
genic architecture thanwhat observed with anNRI (Table III). This
may be consistent with the more selective targets of SSRI drugs.
Similarly to what was observed with the multi-class analysis,
regularization methods including Elastic Net performed sub-opti-
mally. In both cases, classification above chance levels was achieved
but only through careful optimization of the methods. Across all
analysis, validation methods were used to ensure models were not
over-fitted to the data.
Feature Extraction
The top ranking features based on Jaccard distance were extracted
for each of the binary comparisons. A total of 241 probe sets were
uncovered from the nortriptyline (NRI) versus control analysis and
204 from the escitalopram (SSRI) versus control comparison.
Examining the two sets of probes, only 20 probe sets overlapped
across both (<10%) analysis. This finding suggests that the two
drugs have distinct molecular mechanisms of action. Indeed, the
different gene targets could provide clues on the candidate gene sets
that could be used in the search for predictors of differential
treatment response in future human studies. In order to gain
further biological insight the two gene-lists were carried forward
for pathway and network analysis using MetaCoreTM.
Gene Network and Enrichment Analysis
The top ranking probe sets extracted from the nortriptyline and
control classification analysis were uploaded to MetaCoreTM for
pathway and enrichment analysis. A total of 241 probe sets from the
NRI versus control comparison were matched to 206 genes in
MetaCoreTM database (Supplementary Materials 2). First, net-
works were created using uploaded reference molecules as seeds
and interactions with molecules in MetaCoreTM database as edges.
The top scoring networks byP-value andG-Score are reported. The
first pathway, with a P-value of 4.58 1028 and G-Score of 49.06,
containing 14 reference molecules was a network centered on the
CREB1 gene complex (Fig. 1). Several of the uploaded genes show a
direct interaction with Creb1, including ATF Creb, ATF-1,
SLC38A2, Caspase-6, and several others are one interaction
away. The association between CREB1 and its interaction with
BDNF and Met variants is well documented. Phosphorylation of
CREB1 results in the synthesis of different proteins that play an
important role in neuronal cell functioning. In animal models,
increase of CREB1 has been associated with antidepressant- like
effects [Chen et al., 2001a]. CREB mediates the transcription of
genes containing a cAMP-responsive element and is induced by
TABLE I. Summary of Results for the Multi-Class Classification
(Nortriptyline, Escitalopram, and Saline) Analysis
EN SVM L1-SVM
Probesets IG D2 IG D1 ANOVA
37,231 0.41  0.12 0.56  0.08 0.44  0.12
30,000 0.40  0.11 0.55  0.09 0.44  0.14
10,000 0.43  0.10 0.54  0.06 0.40  0.14
1,000 0.42  0.12 0.51  0.10 0.40  0.12
100 0.30  0.14 0.48  0.13 0.42  0.12
10 0.29  0.11 0.34  0.13 0.36  0.14
The table reports the three top performing methods and combination of feature selection of
discretization. Values represent accuracy scoreswith corresponding errors terms. Given that this
is a 3-way multiclass problem, chance accuracy is considered at 33%. The first column reports
the number of probesets used for classification following feature reduction. The second column
shows the results from the Elastic net regularizationmethod, with InfoGain and D2 discretization.
The third column reports the results using Support Vector Machines with InfoGain and D1
discritization. Finally the last column shows the results from the combination of ℓ1—norm
regularization method with SVM with ANOVA for feature reduction. The best classification
performance was achieved with and SVM with infogain and D1 (naive-discretization).
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different factors including neurotrophic and inflammatory signals.
Inflammatory pathways have been implicated in aetiology in the
pathomechanisms of antidepressant efficacy [Chen et al., 2001b]. A
second gene-hub centered on theHistoneH3 gene, which belonged
to the uploaded gene list, is also present in the same network. In
mouse, chronic social defeat stress models have been associated
with increase in H3 acetylation and decreased levels of histone
deacetylase 2 (HDAC2) suggesting that antidepressants may also
act through HDAC inhibition [Covington et al., 2009].
A network highly enriched with canonical fragments with a
gScore of 546.777, P< 3 1003 was also uncovered (Fig. 2). The
network is centered on the NF-kB gene hub with two reference
molecules, CD80 and IkB interacting directly with it. Activation of
CD80 is associated with T-cell proliferation and cytokine produc-
tion, while IkB is an inhibitor of the NF-kB. Stimuli,such as those
induced by cytokins IL-1 can dissociate IkB from the NF-kB
complex making it available to translocate to the nucleus. The
NF-kB hub and reference molecules play a critical role in limiting
cytokine induced cell death. This pathway also suggests an associa-
tion with inflammation.
Lastly gene set enrichment analysis was used to look for the
association between the gene list and known process pathways. The
top ranking process pathway P< 5.9 107, (FDR corrected,
Q< 4.15 1004) is significantly associated with development
of glucocorticoid receptor signaling (Fig. 3). Glucocorticoid family
of genes, including GCR-a are associated with suppression of
NF-kB by increasing expression of IkB which, as discussed previ-
ously, is a potent NF-kB inhibitor. Glucocorticoids are well-
characterized and potent anti-inflammatory and immunosuppres-
sive agents, inhibiting all known cytokine synthesis involved in pro-
inflammatory processes [Almawi and Melemedjian, 2002].
The same analysis was repeated for probe sets uncovered from
the escitalopram versus saline classification analysis. A total of
204 probe sets were identified and matched to 181 genes in
MetaCoreTM database. The first two networks uncovered
were both strongly associated with CREB1, P< 5.7 1022 and
FIG. 1. Top ranking gene network by P-value from the gene list uploaded from the NRI versus Control analysis. Uploaded reference molecules
are identified with a red circle. The pathway is centered on the CREB1 gene hub with several seed genes including the ATF/Creb, Casp6,
Slc38a2, and Acta1 genes, interacting directly with it and several others one interaction away. Creb has been systematically found to be
activated by AD treatment and is a key mechanism involved in hippocampal neurogenesis and inflammation. A second gene hub based on the
uploaded Hdac3 gene was also uncovered. Hdac3 inhibitors have been shown to have antidepressant effects in animal models. [Color figure
can be viewed at wileyonlinelibrary.com].
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P< 5.7 1022, with 14 seed molecules interacting directly with
the CREB1 gene hub in both cases (Fig. 4). These include: VAT-1,
DAD-1, PAQR9, BCKD, BDH, Prickle4, PP2A, RPL13A, SPRED2,
KLP, FAM36A,NAB1,CLSTN3, PEDF-R, and FZD3 (Frizzled gene
previously associated with different psychopathologies, most no-
tably Schizophrenia). Through different mechanisms of action,
networks uncovered for bothNRI and SSRI are strongly involved in
inflammatory processes. The second network, ranked by G-Score
(G-Score¼ 1963.40), is an ephrin receptor signaling pathway,
centered on the c-Src gene hub (Fig. 5). Three genes from the
ephrin family were uploaded as seed molecules. Previous animal
studies have found that ephrin genes, including EphA4 and Eph-
rinA3, were deregulated in animal models of depression and that
these can be rescued by fluoxetine administration [Xiao et al.,
2006]. Pathway analysis from the StarD study also reported a
potential role for the substrate (EFNA5) and receptor (EPHA5)
genes of ephrin-A5, in cluster of genes potentially involved in SSRI
treatment response [Ising et al., 2009]. Similarly a combined
phenotype of treatment outcome in the MARS study was found
with a SNP located downstream of EPHB1. Animal studies suggest
that the ephrin system is involved in the regulation of neural
plasticity in the hippocampus. Indeed, previous studies suggested
that antidepressants may work through stimulation of neurogen-
esis in this brain area [Malki et al., 2015].
We further performed a canonical pathwaymodeling to explore
ontology for enrichment (Fig. 6). The top ranking canonical
pathway (P< 1 10100) was associated with cellular organization
(P< 5.85 1008) and biogenesis (P< 6.6 1008). The pathway
consists of 138 uploaded (seed) genes of which 127 interact directly
with the apoptotic signaling by c-MYC. This may further highlight
a role for both classes of antidepressants in neuronal cell growth in
addition to showing immunological effects.
FIG. 2. Top ranking gene network by gScore from the gene list uploaded from the NRI versus control analysis. The pathway is highly enriched
with fragments of canonical pathways and shows a gene-network centered on the NF-kB gene complex. NF-kB is modulated directly by CREB
suggesting an association with mechanisms involved in modulating inflammatory response. [Color figure can be viewed at wileyonlinelibrary.com].
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MetaCoreTM, allows the comparison of different analyses for
similarities and differences. Common processes across the
two analysis are related to potential inhibition of TFG-b
signaling (P¼ 1.095 102) and cell regulation and proliferation
(P¼ 7.070 104). A network analysis of common objects suggest
an association with pathway (P¼ 4.93 1011) centered on the
C-Jun gene hub involved the regulation of cell developmental
processes and a second equally scored network by P-value associ-
ated centered on Ubiquitin (P¼ 4.93 1011). Given that both
pathways target CREB1 and that IkB is a targeting mechanism to
ubiquitination and subsequent proteasomal degradation, the path-
way seems plausible and relevant to the pathways uncovered from
both analysis [Taylor et al., 2000].
DISCUSSION
This study used a statistical learning approach to uncover and
compare the genomic signature of response to two antidepressant
drugs. The methods of analyses used differ from traditional linear
methods that explore the associations between molecular variants
and a phenotype using a loci-by-loci approach that rank results
based on probability thresholds independently of all other variants.
The methods presented have two advantages: first, they are able to
search for a sparsely distributed signal and capture the predictive
effects of many markers simultaneously; second, they allow one
to reduce the dimensionality of the data and to identify gene
expression changes that are more likely to modulate response to
each of the two drugs. The results from our analysis suggest that
through distinct molecular mechanisms both drugs appear to
modulate the same pathway involving neurotrophic responses
and inflammation.
POLYGENIC ARCHITECTURE OF ANTIDEPRESSANT
TREATMENT RESPONSE
Response to drug treatment must be considered the endpoint of
pharmacokinetic and pharmacodynamic processes including
drug absorption, distribution, interactions, biotransformation,
and putative target binding. It is therefore likely that a number
of complex biological systems in addition to primary targets
are involved in these processes in a time-dependent manner and
that primary drug targets may, in isolation, not be sufficient to
account for these processes. Moreover, the time taken by anti-
depressants to work suggests that additional long-term modula-
tions of cellular and molecular pathways downstream of target
binding are required to induce therapeutic benefits [Malki et al.,
2015].
FIG. 3. Association between the gene list and known processes pathways reveals a role for Glucocorticoids. These are commonly used for the
suppression of inflammation in chronic inflammatory diseases. The convergent evidence across the top-ranking canonical, network and
process pathway suggest a role for NRI in the modulation of inflammatory responses. [Color figure can be viewed at wileyonlinelibrary.com].
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In the current study, mRNA measurements were first used as
features to classify animals into drug treatment group or no drug
highlighting the differential response to treatment. The results
further showed that as the number of features is reduced, classifi-
cation accuracy decreased to chance levels. The highest classifica-
tion accuracy was achieved with approximately 10,000 probe sets
but the signal remained invariant even using the entire array of
probesets. This suggests the absence of a subset of genes of high
penetrance and that response to AD may be a trait with a highly
polygenic architecture. This is consistent with results from human
studies, where no pharmacogenetic associations with clinically
meaningful effects have been found [Tansey et al., 2012]. Interest-
ingly, the signal was sensitive to the algorithm used and traditional
methods generally preferred for sparse data, including the Elastic
net and RFE, did not perform well. Overall, while it was possible to
discern a signal above chance levels, the results remain generally
weak, particularly for escitalopram (67% classification accuracy).
Moreover, the significance of the results must be interpreted in the
context of its error, which suggests that classification is just
marginally above chance levels.
Binary classification comparing each drug group against control
was marginally more accurate for nortriptyline (77%) than for
escitalopram (67%). The results are consistent with existing liter-
ature showing a stronger association with NRI’s rather than with
SSRI’s. Indeed, the only significant result to date across animal
and human studies of AD from the GENDEP study was found
with several common polymorphisms within the PPM1A gene in
response toNRI treatment [Malki et al., 2011]. The results fromour
study suggest that it is likely that in excess of 1,000 genes may be
involved in modulating response to AD, pointing at a complex
molecular architecture of AD response.
TWO AD TREATMENTS SHOW CONVERGING MODES
OF ACTION
With only a 10% overlap between probe sets significantly associ-
ated with NRI treatment and probe sets significantly associated
with SSRI treatment, it would appear the mechanisms of action of
two drugs are fairly distinct. Contrary to this, gene set enrichment
analysis shows that both the predictors of NRI treatment and SSRI
treatment include a network centered on the Cyclic AMP-respon-
sive element-binding protein-1 (Creb-1)molecule. Irrespectively of
the distinct gene sets associated with NRI and SSRI treatment, the
results point at specific overlaps in which these AD response
pathways converge. It is conceivable that differences in these AD
response pathways could, in part, be responsible for the differential
response to AD treatments. Additionally, the overlap in the AD
response pathways could provide insight into important down-
stream molecules mediating biological processes thought to alle-
viate symptoms of depression, such as reduced inflammation and
neurogenesis as well as being implicated in etiology of the disorder.
Creb1 is a transcription factor, which upon phosphorylation
promotes transcription of geneswith a range of functions including
neuronal growth, regeneration, synaptic plasticity, and immune
function [Mayr andMontminy, 2001;Wen et al., 2010]. Congruent
with the findings of this study, Creb1 has been extensively associ-
ated in both the development of MDD and AD response in MDD
patients [Dowlatshahi et al., 1998; Zubenko et al., 2003]. Further
mechanistic investigations of Creb1 report it as a converging point
of several transduction pathways altered by a range of AD treat-
ments and MDD, such as mitogen-activated protein kinase and
Ca2þ/calmodulin dependant protein kinase signal cascades.
BDNF (brain derived neurotrophic factor) [Tao et al., 1998],
transcriptionally regulated by Creb1, is involved in neuronal adap-
tive responses, neurogenesis and neuronal survival and has been
associated with the effects of AD treatment [Ghosh et al., 1994; Tao
et al., 1998; Chen et al., 2001a; Rossi et al., 2006]. It is therefore
likely that BDNF is an important mediator of the association
between Creb1 and AD response. The role of Creb1 in immune
function is also thought to be an important mechanism underlying
the well-established association between inflammation, AD treat-
ment and MDD. Creb1 promotes anti-inflammatory processes via
a number of mechanisms including the inhibition of NF-kB
activity and induction of IL-10 expression [Parry and Mackman,
1997; Miller et al., 2009; Saraiva and O’Garra, 2010].
The top ranking pathway by gScore from the NRI versus control
comparison is (Fig. 3) centred on the NF-kB gene hub which
complements the Creb1 centred pathway ranked by P-value.
FIG. 4. Top ranking gene network by P-value from the gene list
uploaded from SSRI versus control group analysis. The pathway
is centered on the CREB1 gene hub with all uploaded genes
interacting directly with it except one gene that is one interaction
away. As with the NRI pathway, there is a strong association with
inflammatory processes. Although there is minimal overlap
between the genes uncovered across the two analysis both
drugs seem to affect the same networks but through different
mechanisms. The Frizzled gene, a GWAS hit for schizophrenia, was
among the uploaded genes and also shows a direct interaction
with Creb1. [Color figure can be viewed at wileyonlinelibrary.com].
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Furthermore, pathway analysis highlights genes predicting NRI
treatment are primarily under the influence of glucocorticoids
(Fig. 4), which have strong anti-inflammatory effects [Barnes,
1998]. Catecholamines, such as noradrenaline, are released in
response to stress which, through the hypothalamic-pituitary-
adrenal (HPA)-axis, stimulate the secretion of glucocorticoids.
Accordingly, AD treatment has been previously shown to increase
the expression of glucocorticoid receptors in the hippocampus
[Seckl and Fink, 1992]. Glucocorticoids can inhibit NF-kB, thus
down-regulating inflammatory responses through the inhibition of
its target genes [Mukaida et al., 1994]. AD increase glucocorticoid
expression, which inhibit NF-kB, rendering an anti-inflammatory
effect that could potentially mediate the effects of AD. The gluco-
corticoid resistance hypothesis for depression suggests that im-
paired glucocorticoid receptors underlie depression predisposition
and could potentially modulate AD response in some individuals.
Glucocorticoid receptors also interact with CREB-binding protein
(CBP), which acts as a co-activator of transcription. CBP also binds
other transcription factors that compete for the same binding sites.
Studies have shown that depressed patients show higher levels of
pro-inflammatory cytokines, acute phase proteins, chemokines
and cellular adhesion molecules [Raison et al., 2006]. Cytokines
can activate the HPA axis, causing an elevation of systemic gluco-
corticoid levels, and at the same time, they can inhibit glucocorti-
coid receptor function at multiple levels, including the block of its
translocation and the induction of isoforms with reduced capacity
to bind ligand [Pace and Miller, 2009].
The results suggest an association between the anti-inflamma-
tory roles of Creb1 converging mechanisms of action of both
classes of antidepressant drugs. NRIs have anti-inflammatory
effect in part due to inhibition of PI3Ks leading to an increase
in Creb1 [Mercado et al., 2011].
Predictors of SSRI treatment and predictors of NRI treatment
were combined and analysed using gene set enrichment with the
aim of highlighting converging biological pathways that underlie
both AD response and the aetiology of MDD. Two canonical
pathways were returnedwith equal significance (P¼ 4.93 1011),
one centered on c-Jun gene hub, involved in the regulation of cell
developmental processes, and the other centered on Ubiquitin,
important for protein degradation following oxidation.
FIG. 5. Top ranking gene network by gScore from the gene list uploaded from the SSRI versus control analysis. The pathway is highly enriched
with fragments of canonical pathways and shows a gene-network centered on the c-Src gene complex. Several studies have found an
association between Ephrin and antidepressants. Animal studies have found increased levels of ephrinA in response to stress in rats which is
rescued by fluoxetine administration. [Color figure can be viewed at wileyonlinelibrary.com].
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AD TREATMENT SPECIFIC MODES OF ACTION
Although there are significant parallels between the pathways
implicated in both AD treatments, there are also interesting differ-
ences. These differences could be responsible for the differential
response to AD treatments and could be further explored in the
search for biomarkers of AD treatment response in future studies.
Gene network analysis of SSRI treatment predictors, enriched for
canonical pathways, highlighted the importance of the transcrip-
tion factor c-Myc. c-Myc is in part regulated by inflammation and
increased oxidative stress.
A pathway highly enriched with canonical fragments that
includes several ephrin genes was also associated with escitalopram
treatment. Animal models have shown that stress may remodel
neuronal dentrites and spines in the hippocampus but that these
can be rescued by fluoxetine treatment. In mouse, ephrins are
highly expressed in adult hippocampus neurons and play a critical
role in neuronal regulation and synapse formation and plasticity
[Li et al., 2014]. A human pharmacogenetic association study
(MARS) also reported an association between the rs1502174
SNP in the Ephrin type-B receptor gene (P¼ 8.5 105) and
responders to SSRI treatment. The study searched for genetic
FIG. 6. The most significant canonical pathway from the gene list obtained from the esciptalpram versus control analysis. The network
includes objects corresponding to the uploaded gene list and other molecules that interact with them and with each other in canonical
pathways. The pathway consists of 138 uploaded (seed) genes of which 127 interact directly with the apoptotic signaling by c-MYC.
[Color figure can be viewed at wileyonlinelibrary.com].
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markers for early (2 weeks), late responders and remitters (by week
5). The SNP was associated with all three phenotypes [Ising et al.,
2009].
STRENGTHS AND LIMITATIONS
The study used a bottom-up data-driven approach to empirically
test different statistical learning methods to capture a shallow and
sparse signal at the molecular level driven by AD-induced pertur-
bation. These methods offer several advantages compared to
traditional methods but were both computationally expensive
and required careful parameter optimization to avoid over fitting.
In this study, we opted to err on the side of caution, sacrificing
potentially improved accuracy for robustness of results although
this may have increased chances of Type-II errors.
The study explored transcriptomic profiles in a disease relevant
brain region in MDD animal models, which may inform on
potential molecular mechanisms involved in the modulation of
AD response in humans. However, mice are not miniature human
beings and therefore findings require replication in human studies.
Indeed there are several aspects of the trait, including environ-
mental interactions, that simply cannot be modeled in mouse.
However, this study found support for findings reported from the
MARS human pharmacogenetic association study suggesting a role
for the ephrin family gene in SSRI treatment response as well as a
clear role for inflammatory processes.
Additional methods for features reduction could be explored as
part of future studies, which may include SVM-RFEþmRMR to
help overcome some of the limitation of the RFE method which
yielded disappointing results. However this highlights the com-
plexity and structure of the signal we are trying to detect. Robust
Feature Selection (RFS) and Iterative Feature Perturbation (IFP)
could also have been tested [Nie et al., 2010; Canul-Reich et al.,
2012]. A further possibility would be to use grouped LASSO which
applies shared penalties to predetermined groups of features. The
shape of the data sets used can lead to problems such as data shift
induced by train-test split or class imbalance. Although we have
avoided this as much as possible, there exist alternatives to Strati-
fied Cross Validation including Distribution Optimally Balanced
SCV (DOB-SCV) [Moreno-Torres et al., 2012]. Lastly, methods
such as MDLP and experimentation with discretization could be
explored further [Rissanen, 1978].
The results may also point at further higher order complex
interactions and post-translational modification that are not cap-
tured by microarrays or by the methods used and that should be
explored further. Although the assumptions that differential gene
expression is associated with drug action is consistent with existing
literature, expression changes in brain regions other than hippo-
campus and in blood have escaped the current investigation [Malki
et al., 2016]. Future studies could also explore the integration ofML
with convergent methods [Ogden et al., 2004; Le-Niculescu et al.,
2009; Le-Niculescu et al., 2011].
CONCLUSIONS
The goal of pharmacogenomics research is to one day be able to
predict which dose, of what drug will work for which patient at
what time. However, uncovering a biosignature or genetic pre-
dictors of sufficient clinical utility to inform prescription of
antidepressant drugs for an individual patient remains elusive
[Tansey et al., 2012]. A commonly held view was that response
to treatment may be a simpler phenotype than the pathology itself
and indeed many studies exploring the etiology of MDD have used
known targets of therapeutic drugs to inform candidate gene
selection. This study adds to a growing body of literature that
suggests that response to medication may be a more polygenic and
complex trait than previously hypothesized. A deeper understand-
ing of individual differences in AD treatment response should
therefore consider the possible interaction between many molecu-
lar variants, together with miRNA, DNA methylation, histone
modifications and other stochastic factors that may otherwise
modulate gene expression. This study further showed that different
classes of antidepressant drugs target the same pathway associated
with inflammation but through different molecular cascades.
Lastly, we found support for the role on the ephrin gene in response
to SSRI as previously reported in a human pharmacogenetic
association study.
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